Ces radiol. 2014, 68(2):85-96

Transarterial radioembolisation of liver tumors with 90-ytrium microspheres - early experienceOriginal article

Jiří Ferda1, Petr Duras1, Vladislav Třeška2, Tomáš Skalický2, František Šlauf1, Alexander Malán1, Jaroslav Havel1, Jindřich Fínek3
1 Klinika zobrazovacích metod LF UK a FN, Plzeň
2 Chirurgická klinika LF UK a FN, Plzeň
3 Klinika onkologie a radioterapie LF UK a FN, Plzeň

Aim: To evaluate an early experience with transarterial radioembolisation of liver tumors with microspheres with 90-yttrium.

Method: During 6 monnths, we performed 6 months TARE with the application of glass-microspheres TheraSphere®. In 4 patients, colorectal carcinoma metastases were treated, in 2 hepatocellular carcinoma respectivelly. In patients, the peri- and post-procedural disease development was surveyed according complications, WHO performance status an early effect of therapy.

Results: No severe complication was noted, during 6 weeks was noted only one extreme improvement of WHO performance status with decrease by 3 grades, in rest of patients the performance status was unchanged. No progression in liver was noted within 6 weeks.

Conclusion: Our early experience with TARE showed high safety, therapy is well tolerated and the therapy results are promising.

Keywords: 90-yttrium, radioembolisation, metastases of colorectal carcinoma, hepatocellular carcinoma
Grants and funding:

Podpořeno projektem Ministerstva zdravotnictví ČR Koncepční rozvoj výzkumné instituce 00669806 - FN Plzeň a Programem rozvoje vědních oborů Karlovy Univerzity (projekt P36).

Accepted: April 4, 2014; Published: June 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ferda J, Duras P, Třeška V, Skalický T, Šlauf F, Malán A, et al.. Transarterial radioembolisation of liver tumors with 90-ytrium microspheres - early experience. Ces radiol. 2014;68(2):85-96.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Salem R, Thurston KG, Carr BI, Goin JE, Geschwind JF. Yttrium-90 microspheres: radiation therapy for unresectable liver cancer. J Vasc Interv Radiol 2002; 13(9): S223-224. Go to original source... Go to PubMed...
    2. Coldwell D, Sangro B, Wasan H, Salem R, Kennedy A. General selection criteria of patients for radioembolization of liver tumors: an international working group report. Am J Clin Oncol 2011; 34(3): 337-341. Go to original source... Go to PubMed...
    3. Riaz A, Kulik LM, Mulcahy MF, Lewandowski RJ, Salem R. Yttrium-90 radioembolization in the management of liver malignancies. Semin Oncol 2010; 37(2): 94-101. Go to original source... Go to PubMed...
    4. Maleux G, Heye S, Vaninbroukx J, Deroose C. Angiographic considerations in patients undergoing liver-directed radioembolization with 90Y microspheres. Acta Gastroenterol Belg 2010; 73(4): 489-496.
    5. Liu DM, Salem R, Bui JT, Courtney A, Barakat O, Sergie Z, Atassi B, Barrett K, Gowland P, Oman B, Lewandowski RJ, Gates VL, Thurston KG, Wong CY. Angiographic considerations in patients undergoing liver-directed therapy. J Vasc Interv Radiol 2005; 16(7): 911-935. Go to original source... Go to PubMed...
    6. Hamoui N, Minocha J, Memon K, Sato K, Ryu R, Salem R, Lewandowski RJ. Prophylactic embolization of the gastroduodenal and right gastric arteries is not routinely necessary before radioembolization with glass microspheres. J Vasc Interv Radiol 2013; 24(11): 1743-1750. Go to original source... Go to PubMed...
    7. Knesaurek K, Machac J, Muzinic M, DaCosta M, Zhang Z, Heiba S. Quantitative comparison of yttrium-90 (90Y)-microspheres and technetium-99m (99mTc)-macroaggregated albumin SPECT images for planning 90Y therapy of liver cancer. Technol Cancer Res Treat 2010; 9(3): 253-262. Go to original source... Go to PubMed...
    8. Ahmadzadehfar H, Sabet A, Biermann K, Muckle M, Brockmann H, Kuhl C, Wilhelm K, Biersack HJ, Ezziddin S. The significance of 99mTc-MAA SPECT/CT liver perfusion imaging in treatment planning for 90Y-microsphere selective internal radiation treatment. J Nucl Med 2010; 51(8): 1206-1212. Go to original source... Go to PubMed...
    9. Dezarn WA, Cessna JT, DeWerd LA, Feng W, Gates VL, Halama J, Kennedy AS, Nag S, Sarfaraz M, Sehgal V, Selwyn R, Stabin MG, Thomadsen BR, Williams LE, Salem R; American Association of Physicists in Medicine. Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for 90Y microsphere brachytherapy in the treatment of hepatic malignancies. Med Phys 2011; 38(8): 4824-4845. Go to original source... Go to PubMed...
    10. Murthy R, Brown DB, Salem R, Meranze SG, Coldwell DM, Krishnan S, Nunez R, Habbu A, Liu D, Ross W, Cohen AM, Censullo M. Gastrointestinal complications associated with hepatic arterial Yttrium-90 microsphere therapy. J Vasc Interv Radiol 2007; 18(4): 553-561. Go to original source... Go to PubMed...
    11. Salem R, Parikh P, Atassi B, Lewandowski RJ, Ryu RK, Sato KT, Gates VL, Ibrahim S, Mulcahy MF, Kulik L, Liu DM, Riaz A, Omary RA, Kennedy AS. Incidence of radiation pneumonitis after hepatic intra-arterial radiotherapy with yttrium-90 microspheres assuming uniform lung distribution. Am J Clin Oncol 2008; 31(5): 431-438. Go to original source... Go to PubMed...
    12. Lewandowski RJ, Thurston KG, Goin JE, Wong CY, Gates VL, Van Buskirk M, Geschwind JF, Salem R. 90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135-150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic imaging. J Vasc Interv Radiol 2005; 16(12): 1641-1651. Go to original source... Go to PubMed...
    13. Sato KT, Lewandowski RJ, Mulcahy MF, Atassi B, Ryu RK, Gates VL, Nemcek AA Jr, Barakat O, Benson A 3rd, Mandal R, Talamonti M, Wong CY, Miller FH, Newman SB, Shaw JM, Thurston KG, Omary RA, Salem R. Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres-safety, efficacy, and survival. Radiology 2008; 247(2): 507-515. Go to original source... Go to PubMed...
    14. Benson AB 3rd, Geschwind JF, Mulcahy MF, Rilling W, Siskin G, Wiseman G, Cunningham J, Houghton B, Ross M, Memon K, Andrews J, Fleming CJ, Herman J, Nimeiri H, Lewandowski RJ, Salem R. Radioembolisation for liver metastases: results from a prospective 151 patient multi-institutional phase II study. Eur J Cancer 2013; 49(15): 3122-3130. Go to original source... Go to PubMed...
    15. Salem R, Lewandowski RJ, Atassi B, Gordon SC, Gates VL, Barakat O, Sergie Z, Wong CY, Thurston KG. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol 2005; 16(12): 1627-1639. Go to original source... Go to PubMed...
    16. Salem R, Gilbertsen M, Butt Z, Memon K, Vouche M, Hickey R, Baker T, Abecassis MM, Atassi R, Riaz A, Cella D, Burns JL, Ganger D, Benson AB 3rd, Mulcahy MF, Kulik L, Lewandowski R. Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin Gastroenterol Hepatol 2013; 11(10): 1358-1365.e1. Go to original source... Go to PubMed...
    17. Salem R, Mazzaferro V, Sangro B. Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: biological lessons, current challenges, and clinical perspectives. Hepatology 2013; 58(6): 2188-2197. Go to original source... Go to PubMed...
    18. Salem R, Miller FH, Yaghmai V, Lewandowski RJ. Response assessment methodologies in hepatocellular carcinoma: complexities in the era of local and systemic treatments. J Hepatol 2013; 58(6): 1260-1262. Go to original source... Go to PubMed...
    19. Memon K, Kulik L, Lewandowski RJ, Mulcahy MF, Benson AB, Ganger D, Riaz A, Gupta R, Vouche M, Gates VL, Miller FH, Omary RA, Salem R. Radioembolization for hepatocellular carcinoma with portal vein thrombosis: impact of liver function on systemic treatment options at disease progression. J Hepatol 2013; 58(1): 73-80. Go to original source... Go to PubMed...
    20. Sangro B, Salem R, Kennedy A, Coldwell D, Wasan H. Radioembolization for hepatocellular carcinoma: a review of the evidence and treatment recommendations. Am J Clin Oncol 2011; 34(4): 422-431. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content